Agios Adds Alnylam Chief to Board

Xconomy Boston — 

The Cambridge, MA-based cancer drug developer Agios Pharmaceuticals said today it’s tapped John Maraganore, the CEO of Alnylam Pharmaceuticals, to join its board of directors. Maraganore has helped build Cambridge, MA-based Alnylam (NASDAQ:ALNY) into a leading developer of experimental gene-silencing drugs, or RNA-interference therapies. Alnylam’s major corporate partners include Novartis, Roche, and Takeda Pharmaceutical, among others. He joins Agios’s board about two months after the biotech startup announced its $130 million deal with Summit, NJ-based Celgene to develop drugs that starve cancer cells to death.